Poster 1..9999

Total Page:16

File Type:pdf, Size:1020Kb

Poster 1..9999 Accessory molecules 79 OPEN POSTERS Accessory molecules OP1 OP2 Association of invariant chain (CD74) and HLA-DR on Association with atopy of a single nucleotide the surface of transfected fibroblasts detected by polymorphism in the gene encoding the single molecule fluorescence imaging immune-regulatory protein, PD-1 I. Karakikes, I. E. G. Morrison, N. Fernandez & R. J. Cherry E. S. James,à S. J. Davis,à W. O. C. M. Cooksony & M. F. Moffatty University of Essex, Department of Biological Sciences, Wivenhoe Park, ÃNuffield Department of Clinical Medicine, John Radcliffe Hospital, Colchester, CO4 3SQ, UK Headington, Oxford, OX3 9DU, UK, yAsthma Genetics, Wellcome Trust Centre for Human, Genetics, Roosevelt Drive, Headington, Oxford, The interaction of the major histocompatibility complex (MHC) class II- OX3 7BN, UK associated invariant chain (Ii) with MHC class II molecules in the ER facilitates correct assembly and export of class II dimers. It is known that a Programmed Death 1 (PD-1), a new member of the CD28 family of co- proportion of Ii appears at the cell surface, known as CD74 antigen. stimulatory molecules, appears to attenuate T-cell activation. Mice lack- Biochemical data suggest that a proportion of the surface Ii is associated ing PD-1 have been shown to develop a variety of autoimmune diseases, with HLA-DR. We have developed a novel technique based on digital suggesting that PD-1 might be involved in the maintenance of peripheral fluorescence imaging for the study of the association of individual CD74 tolerance. In the PD-1 gene, we have identified an SNP consisting of a and HLA-DR molecules on living cells. Co-localization experiments silent C to T mutation in the cytoplasmic domain-encoding exon at show that 25 Æ 2% of the CD74 forms complexes with HLA-DR abdimers position þ7714 relative to the initiation codon. The SNP has been on the plasma membrane. The data provide for the first time quantitative genotyped in a panel of 364 subjects in 80 nuclear families from a general evidence for formation of HLA-DR:Ii complexes at the surface of antigen population sample from Western Australia. Significant association to total presenting cells. In agreement with this finding, FRET analysis demon- serum IgE levels P ¼ 0Á002 and the skin test index (the sum of skin test strates close proximity of HLA-DR and CD74 at the cell surface of living responses to house dust mite and grass pollen) P ¼ 0Á009 were seen. human transfected fibroblasts. We demonstrate a physical interaction of Association was also found for serum IgE levels to whole Timothy Grass MHC class II and Ii that could account for the recycling of empty HLA- (Phleum pratense) P ¼ 0Á001. Similar results were seen in a replication DR molecules from the cell surface and/or the delivery of newly synthe- panel of 410 subjects. These data are the first to implicate the involvement sized class II:Ii complexes to processing compartments via the cell of the gene in human immune pathology, suggesting that PD-1 may surface. become an important target for immunotherapy. Allergy OP3 mice by discrete classes of chemical allergens are associated with Intracellular cytokine patterns induced in mice by differential frequencies of cells expressing IL-4. chemical contact and respiratory allergens OP4 N. E. Humphreys, R. J. Dearman & I. Kimber The role of antigen presenting cells in Syngenta, CTL, Alderley Park, Macclesfield, SK10 4TJ, UK histamine-induced T helper cell polarization We have demonstrated previously that repeated topical exposure of A. Hogg, B. N. Hudspith, N. B. Rayment & J. Brostoff BALB/c strain mice to the contact allergen 2,4-dinitrochlorobenzene King’s College London, Infection and Immunity Research Group, Division (DNCB) or to the respiratory allergen trimellitic anhydride (TMA) of Life Sciences, 150 Stamford Street, London, SE1 9NN, UK induces, respectively, a selective type 1 or a type 2 cytokine secretion profile in draining lymph node cells (LNC). Using flow cytometry to Type 1 allergic reactions are characterized by the release of mediators, measure intracellular cytokine expression, we have now investigated the including histamine, from mast cells and basophils. It is these mediators relative frequencies of interleukin (IL) 4 and interferon (IFN)-gþ CD4 that induce the characteristic allergic symptoms. However it has been and CD8 cells in the allergen-activated LNC population. The majority of shown that histamine also has a role in regulating the immune response IFN-g was detected within CD8þ cells, with a small subset of CD4þ IFN- that control the events leading to allergic sensitization. Allergic sensitiza- gþ cells; interestingly there were no significant differences between tion is initiated by the development of an aberrant Th2 response against TMA- or DNCB-activated LNC. Quiescent (vehicle-treated) LNC also common environmental antigens. It is known that histamine suppresses had a significant population of CD8þ IFN-gþ cells at approximately half lymphocyte proliferation and Th1 type cytokine production, and this the frequency found in allergen-treated mice. Exposure to TMA induced suppression is more marked in atopic individuals. It has therefore been twice as many CD4þ CD3þ IL-4þ cells, as did treatment with DNCB. A proposed that this is an important factor contributing to the severity and small population of B220þ IL-4þ cells was also observed that was not persistence of allergies. In this study, we show that histamine induces its detectable in populations derived from DNCB- or vehicle-treated mice. observed immunoregulatory effects through modulating antigen present- These data demonstrate that the divergent immune responses induced in ing cell function. Histamine inhibited the uptake of antigen and increased # 2002 Blackwell Publishing Ltd. Immunology, 107, Supplement 1, 79–132 80 Allergy the level of prostaglandin E2 released by these cells. This led to enhanced degrading tight junction proteins. The possible protective role of the production of the cytokine IL-10 and suppressed IL-12 production. These endogenous pulmonary antiprotease secretory leucoprotease inhibitor histamine treated APC’s, when added to antigen, stimulated T cell- (SLPI), however, has not been explored. We investigated the effect of induced polarization of the responses towards a Th2 phenotype. SLPI on the protease activity of immunopurified Der p1. This was measured by the rate of hydrolysis of the substrate N-benzoyl-Phe-Val- Arg-p-nitroanilide. Immunopurified SLPI and sputum containing SLPI OP5 (gift from Professor Stockley) were incubated with Der p1 in ratios of Pigeon fanciers’ lung: exposure to respiratory 0Á1–3 : 1 mol/mol and protease activity measured. Der p1 and SLPI were pathogens and development of disease then incubated (1 : 1 mol/mol) at 378C with DTT in 10 mM phosphate buffer, pH 7Á4, for 30 min and analyzed by SDS–PAGE and silver R. M. Tailford,à A. Todd,à J. E. Calvert,y A. Allen,y S. J. Bourkez & stain. Immunopurified SLPI at physiological concentrations (0Á3–3 mm) C. I. Baldwin§ inhibited the protease activity of Der p1 by 72–81%. Sputum containing ÃPublic Health Laboratory, Cumberland Infirmary, Carlisle, CA2 7HY, 0Á5–2Á0 mm SLPI inhibited activity by 27–58%. SDS–PAGE showed ySchool of Cell and Molecular Biosciences, Medical School, University of cleavage of SLPI by Der p1 after 30 min incubation. In conclusion, Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, zDepartment of immunopurified SLPI and sputum containing SLPI inhibit the protease Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, activity of Der p 1; the SLPI appears to be cleaved during this process. NE1 4LP, §School of Applied Sciences, Northumbria University, Ellison Building, Newcastle upon Tyne, NE1 8ST, UK Pigeon fanciers’ lung (PFL) is caused by hypersensitivity reactions to OP7 inhaled pigeon antigens. Only a small percentage of subjects exposed to HLA associations with sensitization to rats pigeon antigens develop PFL and thus it has been suggested that envir- H. Jeal,à A. Draper,à M. Jones,à J. Harris,à K. Welsh,y A. N. Taylorà & onmental factors, including respiratory infection, may influence the P. Cullinanà immune response and subsequent development of disease. In this study, ÃDepartment of Occupational and Environmental Medicine, yInterstitial serum samples from 156 pigeon fanciers were tested for IgG antibodies to Lung Disease Unit, 1b Manresa Road, London, SW3 6LR, UK a range of organisms known to cause atypical pneumonia and viral lung diseases, which may predispose to PFL. These included influenza A, HLA class II molecules are involved in presenting allergens to T cells and influenza B, respiratory syncitial virus, adenovirus, cytomegalovirus, are therefore likely candidates for controlling the immune response. We Epstein-Barr virus, Mycoplasma pneumoniae, Chlamydia pneumoniae hypothesized that HLA class II genotype might be associated with and C. psittaci. Individuals with PFL were significantly more likely to sensitization to rats among exposed individuals. 109 cases and 397 have had previous infection with influenza B (P ¼ < 0Á003). This suggests referents were HLA typed for DRB1 and DQB1 loci. HLA-DR7 was that infection with influenza B predisposes the development of PFL. associated with sensitization (OR 1Á99), symptoms (OR 2Á98) and sensi- tization with symptoms (OR 4Á81). HLA-DR3 was protective against sensitization (OR 0Á55). We provide a biologically plausible explanation OP6 for these associations. Amino acid analysis of HLA-DR3 and HLA-DR7 The effect of secretory leucoprotease inhibitor on Der reveals that these molecules differ in their hydrophobicity at certain p1 locations. HLA-DR7 is made up of hydrophobic residues whereas HLA-DR3 is made up of hydrophilic residues at the positions where V. Barlow, N. Sehgal, F. Smillie, A. Custovic & A. Woodcock these two molecules differ. The hydrophobic residues of HLA-DR7 may North-west Lung Centre, Wythenshawe Hospital, Manchester, M23 9LT, bind with greater affinity to Rat n 1, which functions in the transport of UK hydrophobic ligands, while the hydrophilic residues of HLA-DR3 may Der p1 exposure is a major risk factor for mite sensitization, yet the total have a negative effect on binding.
Recommended publications
  • Old Road Campus
    Old Road Campus 4a, 4b, 4c, U5 n o t Oxford City Centre g OLD ROAD n i d 4a, 4b, 4c, U5 a e H K O L L A D R O W AD E M I L 4,4a,4b,4c, U1X,U5 A41 42 4,4a,4b,4c,U5 Rin D 4 g R oad 6 7 1 13 3 11 C H U R C H I L L 900 D 2 R I 700, 900 V E E O x f o 5 A C rd 12 C i ty 10 C e n t re B 8 CAR PARK C 9 h u r c R F h i O l l O S H E o V s N E p L i T t DRI a VE ENTRANCE ROOSEVELT DRIVE l 900, ST2 Index 1 The Triangle Nursery 9 Old Road Campus Estates Annexe 13 Boundary Brook House Interserve Joint Research Office Kennedy Institute 2 - Research Services, Medical Sciences Division Old Road Campus Research Building 10 - Clinical Trials and Research Governance 3 New Richards Building Department of Oncology - Human Tissue Governance CRUK/MRC Oxford Institute for Radiation Oncology - Medical Sciences Division Business Development 4 NDM Research Building Institute of Biomedical Engineering Nuffield Department of Primary Care Health Sciences Target Discovery Institute Jenner Institute Medical Sciences Divisional Safety Officers Centre for Tropical Medicine and Global Health Bodleian Knowledge Centre (Library Services) Medical Sciences Division IT Services 5 Wellcome Centre for Human Genetics (WHG) Ludwig Institute for Cancer Research Structural Genomics Consortium 6 Henry Wellcome Building for Molecular Physiology Nuffield Department of Surgical Sciences Loading Bays and Delivery Offices of the Nuffield Professor of Medicine ENTRANCE VIA BUILDING 5 11 Big Data Institute A Wellcome Trust Centre for Human Genetics 7 Henry Wellcome Building for Particle Imaging
    [Show full text]
  • Astrazeneca-Oxford Vaccine Approved for Use in the U.K
    P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe.
    [Show full text]
  • Annual Meeting
    Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign.
    [Show full text]
  • Jenner Institute Complementary Vaccines Platform Technologies
    WHO R&D Blueprint: Janssen Vaccines – Jenner Institute complementary Vaccines Platform Technologies Janssen Vaccines: Jenner Institute: Olga Popova Prof. Sarah Gilbert Jerome Custers WHO Geneva, 21 July 2016 Background • Jenner Institute & Janssen Vaccines presented respective proposals to WHO R&D Blueprint Workshop in April 2016, and were invited to join forces for Round 2 submission • Example of alignment, coordination and partnership between public and private sector stakeholders • Understanding nature of vaccine development, established complementary end‐to‐end skills and capabilities • Long‐term, sustainable & consistent approach and funding • High‐level flexible proposal with illustrative examples • «Bona fide»: collaborative framework to be developed JOINTLY TOWARDS TANGIBLE OUTCOMES x GLOBAL PUBLIC HEALTH 2 Success factors • Available platforms and previous experience with pathogens • Ability to invest time and resources, leverage expertise, minimise opportunity costs and ensure business continuity • Appropriate and functionable operational model, speed • Lean governance, partner alignment and milestone orientation INTERNAL • Reliable & qualified partners, durable commitments • Long‐term reliable funding (min 5‐year horizon) • Resolving vaccination indemnification / liability issue • Consistency in pathogen prioritisation and defined, consistent pre‐ established endpoint commitment • Clear and accelerated / streamlined regulatory pathways, conditions & predictability of licensure EXTERNAL • Anticipated deployment plans and community
    [Show full text]
  • Sir Bryn Terfel Premieres John Rutter's 'Joseph's Carol', Dedicated to the Oxford Vaccine Team in Celebratory Concert Fr
    Sir Bryn Terfel premieres John Rutter’s ‘Joseph’s Carol’, dedicated to the Oxford vaccine team in celebratory concert from the Oxford Philharmonic Orchestra Friday 18 December 2020, 18:30 Streamed on Oxford Philharmonic Orchestra’s YouTube Channel: bit.ly/OPOVaccineTribute Elgar Chanson de Matin William Henry Monk Abide with Me Rodgers & Hammerstein You’ll Never Walk Alone John Rutter Joseph’s Carol WORLD PREMIERE John Rutter Look to the Day Handel Hallelujah Chorus Sir Bryn Terfel bass-baritone Oxford Philharmonic Orchestra Maxim Vengerov violin Choir of Merton College, Oxford John Rutter conductor Alexandra Lowe soprano Marios Papadopoulos conductor Alexander Olleson treble John Suchet presenter In recognition of the formidable work accomplished by the team of scientists at the University of Oxford on their Covid-19 vaccine, the Oxford Philharmonic Orchestra will stream a celebratory concert on Friday 18 December, recorded in the city’s historic Sheldonian Theatre. Performed by bass-baritone Sir Bryn Terfel, the short concert features the premiere of John Rutter’s Joseph’s Carol, written in tribute to the Oxford Vaccine Group, the Jenner Institute and the RECOVERY team. The words by John Rutter recount the long and weary journey of Joseph and Mary to Bethlehem before the birth of the baby Jesus, echoing the programme’s journey from struggle through to hope. Bryn Terfel also joins the Orchestra and the Choir of Merton College, Oxford, in a rousing programme from Rodgers & Hammerstein’s You’ll Never Walk Alone (with Jette Parker Young Artist Alexandra Lowe) to Handel’s Hallelujah Chorus. Sir Bryn and the Orchestra are also joined in the hymn of comfort, Abide with Me, by chorister Alexander Olleson of Christ Church Cathedral Choir, the recent winner of BBC Young Chorister Of The Year 2020.
    [Show full text]
  • Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein
    Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein By Rachel Elizabeth Owen A thesis submitted for the degree of Doctor of Philosophy at the University of London September 2003 The Edward Jenner Institute for Vaccine Research University College London ProQuest Number: U642330 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U642330 Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Hepatitis C virus establishes a persistent infection in approximately 80% of infected individuals. It is unclear why the immune system is frequently unable to mediate a response capable of controlling HCV replication. Dendritic cells (DCs) may be an extrahepatic site of viral replication and it is hypothesised that expression of the core protein within DCs may impair their functions resulting in inadequate immune responses. To investigate potential immunomodulatory effects of the core protein on DCs, replication-deficient adenoviral vectors co-expressing different versions of the core protein (full-length, truncated and a version lacking residues 125-144) with GFP were constructed. Whilst these adenoviruses were being generated, experiments were carried out with an adenoviral vector expressing all the HCV structural proteins (Ad- CE1E2).
    [Show full text]
  • 'Astrazeneca' Covid-19 Vaccine
    Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices.
    [Show full text]
  • Job Description and Person Specificationselection Criteria
    Job title Senior Postdoctoral Scientist Division Medical Sciences Department Nuffield Department of Medicine, Jenner Institute Clinical Centre for Vaccinology and Translational Medicine Location (CCVTM), Old Road Campus, Headington, Oxford, OX3 7LE Grade 8: £41,526 - £49,553 per annum with a discretionary range Grade and salary to £54,131 per annum Hours Full time Contract type Fixed-term contract for 20 months, in the first instance Reporting to Professor Christine Rollier & Professor Cal MacLennan Vacancy reference 147960 Additional Position funded by US funding information Development of a Gonococcal Outer Membrane Vesicle Vaccine Research topic from Lead Optimization to Phase 1 Clinical Trial Principal Investigator Professor Christine Rollier & Professor Cal MacLennan / supervisor Project team Gonococcal Vaccine Group http://www.jenner.ac.uk/ Project web site Funding partner US funding 1. Gottlieb SL, et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 2020; 38: 4362-4373. 2. Micoli, F et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. PNAS 2018; Recent publications 115: 10428-33. 3. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467-478. 4. Marsay L, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect 2015; 71: 326-37. The Role The Gonococcal Vaccine Project is based at the Jenner Institute, University of Oxford, and utilizes a novel outer membrane vesicle (OMV) technology to develop a vaccine against gonorrhoea.
    [Show full text]
  • ASTMH 65Th Annual Meeting Atlanta Marriott Marquis and Hilton Atlanta Atlanta, GA Pre-Registration List As of October 27, 2016
    ASTMH 65th Annual Meeting Atlanta Marriott Marquis and Hilton Atlanta Atlanta, GA Pre-Registration List as of October 27, 2016 *John Aaskov, PhD FRCPath Denise Abud Oladokun Adedamola Adesunloye, Queensland University of Technology Sanofi Pastuer Federal Ministry of Health(FMC) Australia USA Nigeria Neetu Abad Manfred M K Accrombessi Grace Adeya CDC Benin GHSC-PSM/Chemonics United States USA *Jane Winnie Achan, Clinical *Tochukwu Abadom MRC Unit, The Gambia Bwaka Mpia Ado Blackpool Victoria Hospital, United Gambia McKIng Consulting Corporation/ EPI Kingdom DRC Nigeria *Nicole L. Achee, PhD Dem. Republic of Congo Univ of Notre Dame *Shaymaa Abdalal, MD USA Joseph Ado-Yobo Tulane School of Public Hlth Ghana USA Salissou Adamou Bathiri Onchocerciasis & Lymphatic *Valentine Adolphe *Agatha Aboe, MBChB; DO Niger PSI Sightsavers USA Ghana *David P. Adams, PhD MPH MSc Dept of Community Medicine, Mercer Yaw Asare Afrane *Ayokunle Abogan Univ Sch of Medicine Kenya Medical Research Institute Natl Malaria Programme USA Kenya Botswana *John H. Adams, PhD Suneth Agampodi, MBBS MSc *Melanie Abongwa, MSc University of South Florida Coll of Pub Univ of Sri Lanka Iowa State University Hlth Sri Lanka USA USA *Kokila Agarwal, DRPH MBBS MPH *Ahmed Abd El Wahed Abou El Nasr, *Matthew Adams MCHIP/JHPIEGO Georg August University Goettingen Univ of Maryland Baltimore USA Germany USA Kodjovi D. Agbodjavou *Jennifer Abrahams, MD Marc Adamy Jhpiego Corp University of Miami/Jackson Memorial Medicines for Malaria Venture Togo Hospital Switzerland USA Rakesh Aggarwal, MD DM *David Addiss, MD MPH Sanjay Gandhi Postgraduate Inst of Lauren Abrams, GA Task Force for Global Hlth Med Sciences Children Without Worms USA India United States *Ahmed Adeel, MD MPH PhD *Selidji Todagbe AGNANDJI Marcelo Claudio Abril United States CERMEL Fundación Mundo Sano Gabon Argentina *Adeshina Israel Adekunle UNSW *Peter C.
    [Show full text]
  • University of Oxford Oxford OX3 7LE
    Prof Adrian Hill Centre for Clinical Vaccinology & Chief Investigator Tropical Medicine (CCVTM) The Jenner Institute Churchill Hospital University of Oxford Oxford OX3 7LE Recruitment Co-ordinator National Research Ethics Service Tel: 01865 611424 Committee: South Central Oxford A Fax: 01865 289694 Number: 17/SC/0552 Email: [email protected] PARTICIPANT INFORMATION SHEET: MERS001 A study to assess the new candidate MERS-CoV vaccine in healthy adults “A phase I study to determine the safety and immunogenicity of the candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in UK healthy adult volunteers” We would like to invite you to take part in a research study. Before you make a decision, it is important you take the time to understand why the research is being done and what it would involve. Please read the following information carefully and discuss it with friends, relatives and your General Practitioner (GP) if you wish. • Part 1 tells you the purpose of the study and what will happen to you if you take part. • Part 2 tells you more information about the conduct of the study. Please ask us if there is anything that is not clear, or if you would like more information. Take time to decide whether or not to take part. PART 1 What is the purpose of this trial? The purpose of this study is to test a new vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in healthy volunteers. MERS-CoV has been identified as one of the most worrying newly emerging outbreak diseases by many global agencies and expert groups, including the World Health Organization (WHO).
    [Show full text]
  • MALARIA VACCINES for the WORLD 2-4 May 2016, Leiden University Medical Center LUMC, Leiden, the Netherlands
    THE FOURTH INTERNATIONAL CONFERENCE ON: MALARIA VACCINES FOR THE WORLD 2-4 May 2016, Leiden University Medical Center LUMC, Leiden, The Netherlands SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR MVW 2016 With more an estimated 200 million clinical cases annually, resulting in more than 580,000 deaths, malaria is not only an important global health problem but also a major factor limiting economic development in developing countries. Interventions that deploy an effective malaria vaccine are regarded as being one of the most cost-effective and reliable means to limit and ultimately eradicate the disease. In recent years, due to increased funding and research, malaria vaccine development has greatly accelerated. The MVW 2016 conference will look at different aspects of vaccine development, assessment and deployment, as well as funding and regulatory aspects of vaccine implementation and testing. The conference will also highlight research on the use of animal models and (controlled) clinical trials to study the immunological basis of protection and to identify novel candidate vaccine antigens. The MVW 2016 meeting will be of interest to scientists, physicians and other professionals from the academic, industrial/commercial and governmental/policy/regulatory sectors that have an interest in vaccine development and global health. The meeting will include talks on: Malaria vaccine candidate discovery · Novel pre-clinical screening assays/models · Vaccine immunology including system-based approaches · Correlates of protection after vaccination · Pre-erythrocytic vaccines and vaccination · Vaccines for interrupting malaria transmission: role in elimination strategies · RTS,S implementation and refinements · Vaccines against blood stage of malaria infection and multi-stage vaccines · Clinical trials of malaria vaccines controlled human malaria infections (CHMI) and field trials · Relevance and issues related to first in man trials and CHMI studies in endemic countries · Modelling and measuring long-term malaria vaccine impact.
    [Show full text]
  • Isis Insights 63
    The research commercialisation office of the University of Oxford, previously called Isis Innovation, has been renamed Oxford University Innovation All documents and other materials will be updated accordingly. In the meantime the remaining content of this Isis Innovation document is still valid. URLs beginning www.isis-innovation.com/... are automatically redirected to our new domain, www.innovation.ox.ac.uk/... Phone numbers and email addresses for individual members of staff are unchanged Email : [email protected] Ii 63 Spring 11 Issue Isis insights The latest innovations, collaborations and technology transfer Healthy futures Screening for discovery... IiContents Issue 63 Healthy futures Screening for discovery... Tackling Tuberculosis 10 Protein Superglue 26 Patient Reported Outcomes 28 03. Newsflash 18. Transformers The latest news from Isis Lightweight motor magnets 04. The Loop 20. Testing, Testing A news roundup from Oxford University Making test tube research more reliable Consulting and Isis Enterprise 22. Spring Clean 05. The Portfolio Showcasing clean-tech energy systems Investment and spin-out news 24. Fluid Thinking 06. Technology Steps Forward An acoustic separator for a wide audience The latest licence agreements 26. Protein Superglue Identifying proteins linked with diseases 08. Scouting for Success Oxford Innovation Society member Dow Chemical’s investment strategies 28. The PROs of Academic Consultancy Oxford University Consulting helping with 10. Tackling Tuberculosis healthcare A vaccine for the 21st Century 30. Above Sea Level 12. Oxford-Emergent Tuberculosis Isis Enterprise using submarine technology for Consortium Focus health screening Deeper insight into the TB vaccine partnership 16. Inside the Incubator A new initiative for Oxford software Ii is produced by Isis Innovation Ltd, the technology transfer company owned by the University of Oxford.
    [Show full text]